312 related articles for article (PubMed ID: 18035325)
21. Anticytokine therapy in systemic lupus erythematosus.
Yoo DH
Lupus; 2010 Oct; 19(12):1460-7. PubMed ID: 20947558
[TBL] [Abstract][Full Text] [Related]
22. Treatment of lupus nephritis: facing the era of immunotherapy.
Aran AA; Putterman C
Panminerva Med; 2008 Sep; 50(3):235-45. PubMed ID: 18927528
[TBL] [Abstract][Full Text] [Related]
23. Pharmacotherapy of systemic lupus erythematosus.
Francis L; Perl A
Expert Opin Pharmacother; 2009 Jun; 10(9):1481-94. PubMed ID: 19505215
[TBL] [Abstract][Full Text] [Related]
24. Targeting of B cells in SLE: rationale and therapeutic opportunities.
Silverman GJ
Bull NYU Hosp Jt Dis; 2006; 64(1-2):51-6. PubMed ID: 17121490
[TBL] [Abstract][Full Text] [Related]
25. Systemic lupus erythematosus--2005 annus mirabilis?
Isenberg D; Rahman A
Nat Clin Pract Rheumatol; 2006 Mar; 2(3):145-52. PubMed ID: 16932674
[TBL] [Abstract][Full Text] [Related]
26. Novel approaches to the development of targeted therapeutic agents for systemic lupus erythematosus.
Sthoeger Z; Sharabi A; Mozes E
J Autoimmun; 2014 Nov; 54():60-71. PubMed ID: 24958634
[TBL] [Abstract][Full Text] [Related]
27. Rituximab: a promising therapy in systemic lupus erythematosus.
Thatayatikom A; White AJ
Autoimmun Rev; 2006 Jan; 5(1):18-24. PubMed ID: 16338207
[TBL] [Abstract][Full Text] [Related]
28. Lupus: novel therapies in clinical development.
Chugh PK
Eur J Intern Med; 2012 Apr; 23(3):212-8. PubMed ID: 22385876
[TBL] [Abstract][Full Text] [Related]
29. Use of rituximab in patients with systemic lupus erythematosus: an update.
García-Carrasco M; Jiménez-Hernández M; Escárcega RO; Mendoza-Pinto C; Galarza-Maldonado C; Sandoval-Cruz M; Zamudio-Huerta L; López-Colombo A; Cervera R
Autoimmun Rev; 2009 Feb; 8(4):343-8. PubMed ID: 19036350
[TBL] [Abstract][Full Text] [Related]
30. Regulators of B-cell activity in SLE: a better target for treatment than B-cell depletion?
Dolff S; Abdulahad WH; Bijl M; Kallenberg CG
Lupus; 2009 Jun; 18(7):575-80. PubMed ID: 19433456
[TBL] [Abstract][Full Text] [Related]
31. B cell biology: implications for treatment of systemic lupus erythematosus.
Anolik JH
Lupus; 2013 Apr; 22(4):342-9. PubMed ID: 23553777
[TBL] [Abstract][Full Text] [Related]
32. Role of pathogenic auto-antibody production by Toll-like receptor 9 of B cells in active systemic lupus erythematosus.
Nakano S; Morimoto S; Suzuki J; Nozawa K; Amano H; Tokano Y; Takasaki Y
Rheumatology (Oxford); 2008 Feb; 47(2):145-9. PubMed ID: 18160420
[TBL] [Abstract][Full Text] [Related]
33. B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus.
Podolskaya A; Stadermann M; Pilkington C; Marks SD; Tullus K
Arch Dis Child; 2008 May; 93(5):401-6. PubMed ID: 18039744
[TBL] [Abstract][Full Text] [Related]
34. [Immunomodulation therapy for autoimmune diseases. New hope for patients with autoimmune diseases].
Szegedi G
Orv Hetil; 2005 Apr; 146(14):635-43. PubMed ID: 15889537
[TBL] [Abstract][Full Text] [Related]
35. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE.
Vallerskog T; Gunnarsson I; Widhe M; Risselada A; Klareskog L; van Vollenhoven R; Malmström V; Trollmo C
Clin Immunol; 2007 Jan; 122(1):62-74. PubMed ID: 17046329
[TBL] [Abstract][Full Text] [Related]
36. B cell loss leading to remission in severe systemic lupus erythematosus.
Tarrant TK; Frazer DH; Aya-Ay JP; Patel DD
J Rheumatol; 2003 Feb; 30(2):412-4. PubMed ID: 12563705
[TBL] [Abstract][Full Text] [Related]
37. [New concepts for the therapy of systemic lupus erythematosus].
Spertini F
Rev Med Suisse; 2007 Jan; 3(94):98-102. PubMed ID: 17354532
[TBL] [Abstract][Full Text] [Related]
38. Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide): immunomodulation of gene expression.
Sthoeger ZM; Sharabi A; Molad Y; Asher I; Zinger H; Dayan M; Mozes E
J Autoimmun; 2009 Aug; 33(1):77-82. PubMed ID: 19346102
[TBL] [Abstract][Full Text] [Related]
39. Increased T-lymphocyte apoptosis in lupus correlates with disease activity and may be responsible for reduced T-cell frequency: a cross-sectional and longitudinal study.
Dhir V; Singh AP; Aggarwal A; Naik S; Misra R
Lupus; 2009 Aug; 18(9):785-91. PubMed ID: 19578102
[TBL] [Abstract][Full Text] [Related]
40. A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans' syndrome: immunological analysis of B cells, T cells and cytokines.
Tamimoto Y; Horiuchi T; Tsukamoto H; Otsuka J; Mitoma H; Kimoto Y; Nakashima H; Muta K; Abe Y; Kiyohara C; Ueda A; Nagasawa K; Yoshizawa S; Shimoda T; Harada M
Rheumatology (Oxford); 2008 Jun; 47(6):821-7. PubMed ID: 18397955
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
